-
Glipizide
G
971
Glipizide
ATC:
A
108807
Use: antidiabetic
29094-61-9 MF:
C21H27N50,S
MW:
445.54 EINECS: 249-427-6
>3 g/kg (M, i.p.);
1200 mgkg (R, i.p.)
N-[2-[4-[[[(cyclohexylamino)carbonyl]ami1io]sulfonyl]phenyI]ethyl]-5-methylpyrazinecarboxamide
2.
4-(2-arninoethy1)-
5-methylpyrozinc-
benzenesulfonomide
(1)
2-carboxylic
acid
Referencefs):
DAS
2 012 138 (Carlo Erba; appl. l4.Y.1970; I-prior. 26.3.1969, 18.6.1969).
US
3
669 966 (Carlo Erba; 13.6.1972; I-prior. 26.3.1969, 18.6.1969).
Ambrogli,
V.

et al.: Arzneim-Forsch. (ARZNAD) 21, 200
(1
97 1).
NaOH
preparation
of5-methylpyrazinc-2-carboxylic
acid
from
2,s-dimethylpyrazine
via oxidutiort:
Stoehr:
J.
Prakt. Chem. (JPCEAO) (2),
51,
464 (1895).
Stoehr: J. Prakt. Chem. (JPCEAO)
(2),
47,
480 (1 893).
Kiener, A,: Angew. Chem. (ANCEAD)
104
(6),
748 (1992).
Goldberg, Yu.; Shymanska,
M.:
Org. Prep. Proced. Int. (OPPIAK) 23 (2), 188 (1991).
cyclohexyl
electrochemical preparation of
5-methylpyrazine-2-carboxylic
acid:

Borsotti, G.P.;
Foh,
M.; Gatti, N.: Synthesis (SYNTBF)
1990
(3), 207.
Feldman, D. et al.: Chem. Heterocycl. Compd.
(N.
Y.)
(CHCCAL)
31
(l), 80 (1995).
GI:pizide
Formulation(s):
tabl. 2.5 mg, 5 mg, 10
mg
isocyanate
Trade
Name(s):
D:
Glibenese (Pfizer; 1977.) Osidia cp
B
lib ~nodifike
I:
Minidiab (Carlo Erba;
F: GliEn6se (Pfizer; 1974) (CC) (Pfizer) 1972)
Minidiab (Pharmacia
&
GB: Glibenese (Pfizer; 1975) USA: Glucotrol (Pfizer; 1984)
Upjohn; 1974) Minodiab (Pharmacia
&

Upjohn; 1975)
Gliquidone
ATC: AlOBBO8
Use: antidiabetic
RN: 33342-05-1 MF:
C,,H,,N,O,S MW: 527.64 EINECS: 251-463-2
LD,,:
234 mdkg
(M,
i.v.); >2glkg (M,
p.0.)
CN:
N-~(cyclohexylan1ino)carbonyl]-4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1
H)-
972
G Glisoxepide
I.
HNO,
2.
Hz,
Roney-Ni
3.
NoNO2
4.
oq.
H,SO,
5.
H,c-O\
S
$'

1.
NaOH
oQ
\,+H,
,
H3c,0y$f~3
2.
H2S04
,
,
0
H,C
CH,
7-methaxy-2,4,4-
trimethyl-
1.2.3.4-
tetrahydroiso-
quinoline- 1.3-dione
4.4-dirnethyi-7- 4-(2-orninoethy1)-
metnoxyisochrornon-
benzenesulfonamide
1.3-dione
(I)
I1
+
cyclahexyl-
potassium
isocyanate
tert-butylate
Gliquidone

Reference(s):
DAS
2
000 339 (Thomae; appl. 5.1.1970).
DOS 2 01
1
126 (Thomae; appl. 10.3.1970).
US 3 708 486 (Boehringer Ing.; 2.1.1973; D-prior. 5.1.1970 and 17.4.1969).
Formulation(s):
tabl. 30 mg
Trade Name(s):
D: Clurcnorm (Yamanouchi) GB: Glurenorm (Sanofi
I:
Glurenor (Guidotti)
Winthrop)
Glisoxepide
ATC: AlOBBll
Use: antidiabetic
RN: 25046-79- 1
MF:
C20H27N505S MW: 449.53 EINECS: 246-579-5
LD,,,: 283 mglkg
(M,
i.v.);
>10 gkg
(M,
p.0.);
196
mglkg
(R,

i.v.); >10 g/kg
(R,
p.0.);
>2
glkg (dog,
p.0.)
CN:
N-[2-[4-[[[[(hexahydro-lH-azepin-l-yl)amino]carbonyl]amino]sulfonyl]phenyl]ethy1]-5-methyl-3-
isoxazolecarboxamide
!"
Glucametacin
G
973
1
S0CI2
0
OYOOH
+I
"3C
2. 4-(2-ominoethy1)-
H3C
methyl
benzenesulfonom~de chloroformote
5-rncthylisoxozolc-
3-corboxylic acid
H3C
(1)
I
-ominohem- Glisoxepida
hydroozepine

L
Rejerence(s):
DE
1
670
952 (Bayer; appl. 25.11.1967).
US
3
668
215 (Bayer; 6.6.1972; D-prior. 25.11.1967).
Plbmpe,
H.
et al.: Arzneirn Forsch. (ARZNAD)
24,
363 (1974).
Formulntion(s):
tabl. 4
mg
Trade
Namels):
D:
Pro-Diaban (Bayer Vital)
I:
Glucoben (Farrnadcs); wfm
Glucametacin
ATC:
A02A
Use: anti-inflammatory
RN:
52443-21 -7

MF:
C25H2,C1N20~
MW:
5 18.95 EINECS: 257-923-9
CN:
2-[[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyI]arnino]-2-deoxy-~-glucose
indornetacin
(9.
v.)
1
-(4-chlorobenzoyl)-2-
methyl-5-methoxyindol-
3-acetyl chloride
(I)
n-D-glucosarnine
hydrochloride
Glucornetocin
Referencefs):
DOS 2 223 051 (SIR; appl. 12.5.1972; I-prior. 9.5.1972).
Formulation(s):
cps. 70 mg, 140 mg
Trade Name(s):
I: Teorema (Farmades); wfm Teoremac (Sir); wfm
D-Ghcosamine
ATC: MOlAXOS
(Chi
tosamine)
Use: antirheumatic, antiarthritic
RN: 3416-24-8 MF:
C,H,,NO, MW: 179.17 EINECS: 222-31 1-2

CN:
2-amino-2-deoxy-D-glucose
hydrochIoride
RN: 66-84-2 MF: ChH,,NOs
.
HCI MW: 215.63 EINECS: 200-638-1
sulfate
(2:l)
RN: 14999-43-0 MF: ChHl,NO,. 1/2H,04S MW: 456.42 EINECS: 239-088-2
hydriodide
RN: 14999-44-1 MF: C6H13N05. HI MW: 307.08 EINECS: 239-089-8
Unit of chitin, mucoproteins and mucopolysaccharids, obtained by hydrolysis with HCI.
Referencefs):
Ledderhose, G.: Z. Physiol. Chem. (ZPCHAS) 2, 213 (1878).
preparation of glucosarnine salts:
GB 1 056 33 1 (Rotta Research; appl. 15.1.1964; I-prior. 18.1.1963),
stable complex from
glucosamine sulfate
and
NaCI:
GB 2 101 585 (Rotta Research; appl. 26.4.1982; I-prior. 30.4.1981).
combinarion of
glucosamine sulfate
and
hydriodide
for therapy of rheumatoid arthritis and osteoarthritis:
US 3 683 076 (L. Rovati; 8.8.1972; I-prior. 26.10.1968).
Glutethimide
G
975

Formulation(s):
drg. 200 mg, 250 mg (as sulfate); vial 400 mg (as sulfate)
Trade Nameis):
D: Dona-200 S (Opfermann) I: Dona (Rottapharm; as
sulfate)
Glutethimide
ATC: NOSCEOI
Use: hypnotic, sedative
RN: 77-21-4 MF: C13H,5N0,
MW:
217.27 EINECS: 201-012-0
LD,,: 360 mglkg (M, p.0.);
600 mgkg (R, p.0.);
500 mglkg (dog, p.0.)
CN:
3-ethyl-3-phenyl-2,6-piperidinedione
methyl 2-phenyl-
ocrylate butyronitrile
Glutethimide
I
Reference(s):
US
2 673 205 (Ciba; 1954; CH-prior. 195 1).
DE 9.50 193 (Ciba; appl. 1952; CH-prior. 195
1).
Formulation(s):
cps.; tabl. 250 mg, 500 mg
Trade Nameis):
D: Doriden (Ciba); wfm
I:

Doriden (Ciba); wfm USA: Doriden (USV); wfm
F:
DoridCne (Ciba): wfm
J:
Doriden (Ciba-Geigy- generic
GB: Doriden (Ciba); wfm Takeda)
Glybuzole
(Desagl
y
buzole)
ATC: V03AH
Use: antidiabetic
RN: 1492-02-0 MF:
CI2HI5N3O2S2 MW: 297.40 EINECS: 216-081-2
LD,,,: 193 mglkg(M,i.v.); 550 mg/kg(M,p.o.);
500 mglkg (R, p.0.)
CN:
N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]benzenesulfonamide
benzene- 2-omino-5-tert-
sulfonyl butyl-
1,3,4-
chloride thiadiozole
Glybuzole
Referenceis):
GB 822 947 (Smith
&
Nephew; appl. 1957; valid from 1958).
FR-M
3 389 (RhGne-Poulenc; appl. 27.1.1964).
976

G
Glyconiaxide
Forndation(s):
250 mg (oral)
Trade Name(s):
J: Gludiase (Kyowa Hakko)
Glyconiazide
(Gluconiazide)
ATC: J04A
Usc: tuberculostatic
RN: 3691-74-5 MF: Cl,H13N30,
MW:
295.25 EINECS: 223-005-1
LD,,,: 641 mglkg
(M,
i.v.); 748 mgkg
(M,
p.0.);
1763 mgkg (R, i.v.); 6423 mgkg (R, p.0.)
CN:
glucuronic acid
y-lactone 1
-[(4-pyridinylcarbonyI)hydrazone]
Reference(s):
US 2 940 899 (Univ. of California; 14.6.1960; prior. 28.9.1953).
Sah, P.P.T.: J. Am. Chem. Soc. (JACSAT) 75,2512 (1953).
isoniozid D-qlucuronoloctone
Formulation(s):
(oral) 0.01 5 g/kg
Glyconiozide

Trade Narne(s):
D: Gluronazid (Hormon- Isozidoron
444
I: Glucazide (Stholl);
wfm
Chemie); wfm (Saarstickstoffl-comb.;
J:
Hy dronsan (Chugai)
-
wfm
(9.
v.)
Glycopyrronium bromide
(Glycopyrrolate)
ATC: A03AB02
Use: anticholinergic, antispasmodic
RN: 596-51 -0 MF: C,,H,,BrN03
MW:
398.34 EINECS: 209-887-0
LD,,,: 15 mgikg
(M,
i.v.); 570 mgikg
(M,
p.0.);
709 mgkg (R, p.0.)
CN:
3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium
bromide
HC
+

OH
b
I
'0
J-hydroxy-
0
1
-methyl-
pyrrolidine
methyl phenyl- cyclopenty\- methyl
glyoxylate magnesium a-cyclopentyl-
bromide mandelote
Glymidine
G
977
(1)
(
Glycopyrroniurn bromide
Reference(s):
US
2
956 062
(A.
H. Robins; 11.10.1960; prior. 26.2.1959)
Formulation(s):
amp. 0.2 mgfml, 500 pglml
Trade Nanie(s):
D: Robinul (Brenner-Efeka) GB: Robinul (Anpharm)
F:
Adcryl (Martinet); wfm

J:
Robinul (Kaken)
USA: Robinul (Robins)
Glyrnidine
(Glycodiazin)
ATC: AlOBCOl
Use: antidiabetic
RN:
339-44-6 MF: C13H15N304S MW: 309.35 EINECS: 206-426-5
LD,,: 3100mgkg (R, p.0.)
CN:
N-[5-(2-methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide
sodium
salt
RN:
3459-20-9 MF: Cl3Hl4N3NaO,S MW: 331.33 EINECS: 222-399-2
LD,,: 3100 mgkg (R, p.0.)
dimethyl-
1
,I
.2-tris(2-rnethoxyethoxy)-
farmamide
ethane
Reference
(s):
US
3
275
635 (Schering AG; 27.9.1966; D-prior. lR.10.1960, 22.2.1961,23.2.1961).
DAS

1
445 142 (Schering AG; appl. 22.2.1961).
DAS
1
445 146 (Schering AG; appl. 9.9.1961; addition to DAS 1 445 142).
Gutsche,
K.
et al.: Arzneim Forsch. (ARZNAD)
14,
373 (1964).
benzenesulfonyl-
Formulation(s):
tabl. 0.5 g, 1 g (as sodium salt)
Glyrnidine
Trade Name(s):
D: Redul (Bayer-Schering); wfm
guanidine
978
G
Granisetron
Redul plus (Bayer- F: Glyconormal (Bayer-
I:
Glycanol (Bayer); wfm
Schering)-comb, with Pharma); wfm Gondafon (Schering); wfm
buformin; wfm
Gondafon (SEPPS); wfm J: Lycanol (Bayer-Yoshitomi)
Redul28 (Schering); wfrn GB: Gondafon (Schering
Chemicals); wfrn
Granisetron
(BRL-43694)

ATC: A04AA02
Use: anti-emetic, 5-HT,-antagonist
RN: 109889-09-0 MF: C,,H2,N40 MW: 312.42
CN:
endo-l-methyl-N-(9-methyl-9-azabicyclo[3.3.l]non-3-yl)-1H-indazole-3-carboxamide
monohydrochloride
RN: 107007-99-8 MF: C,,H,,N,O. HCI MW: 348.88
LD,,,: 17 mgkg (M,
i.v.);
350 mglkg (M, p.0.);
14 mglkg (R, i.v.); 350 mgkg (R, p.0.)
COOH
COC
IH
chloride
indarole-3- methyl
carboxylic acid iodide
1
-methyl-
indazole-3-
carboxylic acid
Reference(s):
EP 200 444 (Beecham; appl. 21.4.1986; GB-prior. 27.4.1985, 21.10.1985).
Bermudez, J. et al.: Bioorg. Med. Chem. Lett. (BMCLE8)
4
(20), 2376 (1994).
1
-methyl- endo-9-methyl-
alternurive synthesis:
WO 9 730 049 (SmithKline Beecham; appl. 11.2.1992; GB-prior. 13.2.1996).

Granisetron
synthrsis of
1-methylindazole-3-carboxylic
acid:
EP 323 105 (Beecham; appl. 19.12.1988; GB-prior. 22.12.1987).
Bermudez,
J.
et
a].: J. Med. Chem. (JMCMAR)
33,
1924 (1990).
indazole-3- 9-azobicyclo[3.3.1]-
carbonyl chloride
(I)
nanan-3-amine
(granatanearnine)
synthesis of
granataneamine:
Jones, G.; Stanger, J.: J. Chem. Soc. C (JSOOAX) 1969,901.
medic~tl use for freutment of
CNS
und cognitive disorders:
EP 223 385 (Beecham; appl. 7.10.1986; GB-prior. 21.10.1985).
EP 279 990 (Glaxo; appl. 16.12.1987; GB-prior. 17.1 2.1986, 25.3.1987).
Grepafloxacin
G
979
,
.
medical use for treatment of withdrawal syndrome:

EP278 161 (Glaxo; appl. 20.1 1.1987; GB-prior. 21.11.1986, 25.3.1987).
EP 279 114 (Glaxo; appl. 20.11 .I 987; GB-prior. 21.11.1986,25.3.1987).
medical use for treatment of visceral pain:
EP 279 512 (Beecham; appl. 18.1.1988; GB-prior. 19.1.1987).
US
4 845 092 (Beecham; 4.7.1989; appl. 19.1.1988; GB-prior. 19.1.1987).
medical use for treatment of cough and bronchoconstriction:
EP 340 270 (Beecham; appl. 14.1 1.1988; GB-prior. 14.1 1.1987).
medical use for treatment of myocardial instability:
WO
9 109 593 (Beecham; appl. 20.12.1990; GB-prior. 21.12.1989).
Formulation(s):
amp. 1 mg, 3 mg; tabl. 1 mg (as hydrochloride)
Trade Narne(s):
D:
Kevatril (Bristol-Myers GB: Kytril (SmithKline
SquibbISmithKline Beecham)
J:
Beecham)
I: Broncosedina (Farma>-
F:
Kytril (SmithKline comb. USA:
Beecham; 199 1) Kytril (SmithKline
Beecham)
Grepafloxacin
(OPC-
17
1
16)
Sedobex (Ecobi)-comb.

Kytril (SmithKline
Beecham)
Kytril (SmithKline
Beecham)
ATC: JOlMAll
Use: antibacterial (gyrase inhibitor)
RN: 119914-60-2 MF:
CIYH,,FNO3 MW: 331.39
CN:
l-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-l-piperazinyl)-4-oxo-3-quinolinecarboxylic
acid
(?)-form
RN: 146863-02-7 MF: C,,H,,FNO, MW: 33 1.39
(t)-monohydrochloride
RN: 161967-81-3 MF: CIyH,,FNO3
.
HCI MW: 367.85
LD,,,:
69.2 mglkg (M, i.v.); 3900 mglkg (M, p.0.);
152 mglkg (R, i.v.); 3029 mg/kg.(R, p.0.)
1.
S0Cl2
2.H3CvOn0,CH3
0
0
Mg,
C2H50H,
toluene, 60
'C
2.

diethyl rnalonote
F
OvCH3
CH3
Fm-cH3
CH3
0 0
2-methyl-3.4.6- diethyl (2-methyl-
trifluorobenroic
acid
3,4,6-trifluorobenzoyl)-
rnalonate
(I)
980
G
Grepafloxacin
\/
.
C2H50H,
0
OC
1
-
2.
ocetic anhydride cyclopropylomine
triethoxyrnethane
CH~O
6;
ethyl 2-(2-methyl-
3.4.6-trifluorobenzayl)-

3-etho~yacr~late
ethyl 2-(2-methyl-
3.4.6-trifluorobenzoy1)-
3-cyclopropylamino-
acrylate
(11)
ethyl
1
-cyclopropyl-
6.7-difluoro-5-methyl-
1,4-dihydro-4-0x0-
quinaline-3-carboxylote
(In)
2-methyl-
piperaline
1.
NoOH.
C2H50H
2.
HCI
Iv-
F
H3ChNm
CH,O COOH
Grepafloxacin
Reference(s):
EP 287 951 (Otsuka Pharrn.; appl. 14.4.1988; J-prior. 16.4.1987).
EP 364 943 (Otsuka Pharrn.; appl. 17.10.1989; J-prior. 20.10.1988).
melt-extruded polymeric material:
JP 08 280 790 (Otsuka Pharrn.; appl. 17.4.1995).

use as,fungicide:
JP 07 149 647 (Daiichi Seiyaku; appl. 8.9.1994; USA-prior. 8.9.1993).
Formulation(s):
f.
c. tabl. 400 rng, 600 rng (as hydrochloride)
Trccdc Ntrrrre(s);
D:
Vaxar (Glaxo Wellcornel
J:
Lungaskin (Otsuka; as USA: Raxar (Glaxo Wellcome;
Cascan); wfm hydrochloride); wfrn 1997); wfrn